From the past few years, the state has faced
uncertain changes in the rate of employment.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an
uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to
changes in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«Future land transitions are
uncertain but relatively small
changes in afforestation from agriculture resulted
in substantial decrease
in accumulation
rates,» said Coulston.
The timing of these tax
rate changes is still
uncertain, but many believe they will be effective
in 2016.
Further growth of Nevada's distributed PV sector, however, is
uncertain because Nevada's Public Utility Commission recently approved several
changes to the net - metering tariffs, including phasing
in lower net - metering compensation
rates and higher monthly fixed charges for distributed PV customers.
«Given the
uncertain political climate after the elections and the start of the new «
rate - payer impact statement» next year, we worry the window to achieve some of the most meaningful climate
change legislation
in over a decade will close at midnight Wednesday.»
My personal views are: (1) Yes, it is true that increasing greenhouse gas concentrations will tend to warm the Earth's surface and atmosphere; (2) Yes, human production of CO2 is producing significant increases
in CO2 concentration; (3) The
rates of
change of temperature
in the previous two millennia are
uncertain because proxies have been misapplied by the hockey stick crowd.
In addition, the rate of warming for a given CO2 trajectory is sensitive to both positive (CO2) and negative (aerosol) forcings, and so higher sensitivity to both will change in the trend in an uncertain direction depending on the balance of these forcing
In addition, the
rate of warming for a given CO2 trajectory is sensitive to both positive (CO2) and negative (aerosol) forcings, and so higher sensitivity to both will
change in the trend in an uncertain direction depending on the balance of these forcing
in the trend
in an uncertain direction depending on the balance of these forcing
in an
uncertain direction depending on the balance of these forcings.
Thus absent dramatic
changes in water resource management the long term prognosis is clearly one of acceleration — albeit at an
uncertain rate.
Because the basics of anthropogenic global warming are fairly straightforward — CO2 is a greenhouse gas, because of the lapse
rate water vapor condenses or freezes out
in the troposphere and acts mainly to amplify the effect of CO2, humans are burning a lot of fossil C and increasing the CO2
in the atmosphere, the surface of the earth is warming, the cryosphere is retreating, the climate that supports civilization is rapidly
changing, and consequently we are facing an
uncertain future — but the details are complex, it's easy to «misunderestimate» the way climate works
in detail.
Definitional variation over time also means that we are
uncertain as to how much of the
change in the cumulative risk for confirmed maltreatment is due to actual
changes in rates of maltreatment vs
changes in definitions of maltreatment.
While these two variables — how much the interest
rate will
change and over what period of time — remain
uncertain in each cycle, what is absolutely certain is that interest
rates will rise and drop over time as the interest
rate cycle completes itself.